AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15114391 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular pacing
Number of subjects: 0
Study 15114391 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic methods for patient selection
Number of subjects: 0
Study 11531681 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron 4 mg (2 mg.ml‐1 solution) diluted into a 5‐ml solution
Number of subjects: 60
Study 11531681 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg lidocaine (5 ml 1% solution)
Number of subjects: 60
Study 11531681 — intervention group
Group type: COMPARATOR
Intervention: 5 ml of intravenous 0.9% sodium chloride solution (placebo)
Number of subjects: 60
Study 9430812 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 37
Study 9430812 — intervention group
Group type: EXPERIMENTAL
Intervention: Maprotiline
Number of subjects: 37
Study 9430812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 8517715 — intervention group
Group type: EXPERIMENTAL
Intervention: Probenecid
Number of subjects: 0
Study 8517715 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol riboside
Number of subjects: 0
Study 3155379 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinia melanoma oncolysate (VMO) at higher doses (1.5 and 2.0 mg) with immediate treatment schedule
Number of subjects: 48
Study 3155379 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinia melanoma oncolysate (VMO) with delayed treatment schedule
Number of subjects: 48
Study 3155379 — intervention group
Group type: COMPARATOR
Intervention: Control group (pretreatment sera)
Number of subjects: 48
Study 3155379 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-HLA antibody and circulating immune complexes
Number of subjects: 48
Study 31774306 — intervention group
Group type: EXPERIMENTAL
Intervention: Intragastric quinine 600 mg (Q600)
Number of subjects: 27
Study 31774306 — intervention group
Group type: EXPERIMENTAL
Intervention: Intragastric quinine 275 mg (Q275)
Number of subjects: 27
Study 31774306 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 27
Study 29353026 — intervention group
Group type: EXPERIMENTAL
Intervention: Lebrikizumab 125 mg every 4 weeks
Number of subjects: 209
Study 29353026 — intervention group
Group type: COMPARATOR
Intervention: Placebo every 4 weeks
Number of subjects: 209
Study 27184735 — intervention group
Group type: EXPERIMENTAL
Intervention: Reiki with Music Group
Number of subjects: 37
Study 27184735 — intervention group
Group type: COMPARATOR
Intervention: Music Only Group
Number of subjects: 37
Study 25752109 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure drainage
Number of subjects: 102
Study 25752109 — intervention group
Group type: COMPARATOR
Intervention: Control group (no negative pressure drainage)
Number of subjects: 102
Study 23435143 — intervention group
Group type: EXPERIMENTAL
Intervention: Dai-kenchu-to (DKT) 2.5 g administered orally three times a day from postoperative day (POD) 1
Number of subjects: 32
Study 23435143 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 32
Study 19812935 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate infusion (n = 6)
Number of subjects: 12
Study 19812935 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion (n = 6)
Number of subjects: 12
Study 18294318 — intervention group
Group type: EXPERIMENTAL
Intervention: Daylight-PDT (continuous activation of porphyrins)
Number of subjects: 29
Study 18294318 — intervention group
Group type: COMPARATOR
Intervention: Conventional red LED light-PDT (37 J cm(‐2))
Number of subjects: 29
Study 18294318 — intervention group
Group type: COMPARATOR
Intervention: Conventional red LED light-PDT
Number of subjects: 29
Study 15808240 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants and zinc supplementation
Number of subjects: 3294
Study 12554899 — intervention group
Group type: EXPERIMENTAL
Intervention: Pigtail drainage combined with anti-TB drug treatment
Number of subjects: 61
Study 12554899 — intervention group
Group type: COMPARATOR
Intervention: Only anti-TB drugs
Number of subjects: 61
Study 11054390 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-ribavirin combination therapy for 24 weeks
Number of subjects: 53
Study 11054390 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-ribavirin combination therapy for 48 weeks
Number of subjects: 53
Study 11054390 — intervention group
Group type: COMPARATOR
Intervention: Interferon monotherapy
Number of subjects: 53
Study 8814494 — intervention group
Group type: EXPERIMENTAL
Intervention: Steam-PS dialyser
Number of subjects: 31
Study 8814494 — intervention group
Group type: COMPARATOR
Intervention: ETO-PS dialyser
Number of subjects: 31
Study 8814494 — intervention group
Group type: COMPARATOR
Intervention: Cuprophan dialyser
Number of subjects: 31
Study 1323324 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH (1 mg i.m. in long-acting form)
Number of subjects: 64
Study 6830408 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 0
Study 6830408 — intervention group
Group type: COMPARATOR
Intervention: Oxazepam
Number of subjects: 0
Study 31841498 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 μg daily vitamin D supplementation
Number of subjects: 761
Study 31841498 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 μg daily vitamin D supplementation
Number of subjects: 761
Study 31841498 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 761
Study 31841498 — intervention group
Group type: EXPERIMENTAL
Intervention: Low 25(OH)D haplotypes
Number of subjects: 761
Study 31841498 — intervention group
Group type: EXPERIMENTAL
Intervention: High 25(OH)D haplotypes
Number of subjects: 761
Study 29883188 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflexology
Number of subjects: 164
Study 29883188 — intervention group
Group type: COMPARATOR
Intervention: Standard analgesic care (Control)
Number of subjects: 164
Study 29883188 — intervention group
Group type: COMPARATOR
Intervention: Comparison of reflexology vs standard care
Number of subjects: 164
Study 26519116 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi-weekly rotation exercise classes (n=20)
Number of subjects: 35
Study 26519116 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (n=15)
Number of subjects: 35
Study 23548378 — intervention group
Group type: EXPERIMENTAL
Intervention: SMR conditioning training
Number of subjects: 24
Study 23548378 — intervention group
Group type: COMPARATOR
Intervention: Sham conditioning training
Number of subjects: 24
Study 23377594 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based intervention program
Number of subjects: 58
Study 23377594 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonequivalent)
Number of subjects: 58
Study 20199846 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-setting strategy (mental contrasting), cognitive behavioral therapy-oriented problem-solving approach, goal-pursuit strategy (implementation intentions)
Number of subjects: 60
Study 20199846 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine treatment)
Number of subjects: 60
Study 18018417 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch therapy (injectable quinolone switched to oral quinolone)
Number of subjects: 35
Study 18018417 — intervention group
Group type: COMPARATOR
Intervention: Intravenous administration of carbapenem antibacterial agent
Number of subjects: 35
Study 16287366 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (CM; 0.3 g.kg(‐1).day(‐1) + 20 g Polycose)
Number of subjects: 26
Study 16287366 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 26
Study 16287366 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacto-ovo-vegetarian diet (LOV)
Number of subjects: 26
Study 12403203 — intervention group
Group type: EXPERIMENTAL
Intervention: Static magnets
Number of subjects: 20
Study 12403203 — intervention group
Group type: COMPARATOR
Intervention: Placebo magnets
Number of subjects: 20
Study 10444418 — intervention group
Group type: COMPARATOR
Intervention: Insulin infusion (0.25, 0.50, and 1 mU.kg(‐1).min(‐1)) in healthy controls
Number of subjects: 30
Study 10444418 — intervention group
Group type: COMPARATOR
Intervention: Insulin deprivation or insulin replacement in type 1 diabetic subjects
Number of subjects: 30
Study 10444418 — intervention group
Group type: COMPARATOR
Intervention: Normal saline in healthy controls
Number of subjects: 30
Study 7816064 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (25 mg once weekly)
Number of subjects: 141
Study 7816064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study 7816064 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 141
Study 6760680 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 39
Study 6760680 — intervention group
Group type: COMPARATOR
Intervention: Hydralazine
Number of subjects: 39
Study 31149870 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted multicomponent vaccine (CPS5/CPS8/α-toxin/ClfA)
Number of subjects: 0
Study 31149870 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-adjuvanted multicomponent vaccine (CPS5/CPS8/α-toxin/ClfA)
Number of subjects: 0
Study 31149870 — intervention group
Group type: EXPERIMENTAL
Intervention: α-toxin
Number of subjects: 0
Study 31149870 — intervention group
Group type: EXPERIMENTAL
Intervention: ClfA
Number of subjects: 0
Study 31149870 — intervention group
Group type: EXPERIMENTAL
Intervention: EbhA/IsaA/SdrE
Number of subjects: 0
Study 31149870 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-10
Number of subjects: 0
Study 31149870 — intervention group
Group type: EXPERIMENTAL
Intervention: MRPII, IsdA, and ClfA
Number of subjects: 0
Study 30416089 — intervention group
Group type: EXPERIMENTAL
Intervention: Active ABM
Number of subjects: 123
Study 30416089 — intervention group
Group type: COMPARATOR
Intervention: Placebo ABM
Number of subjects: 123
Study 30416089 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control
Number of subjects: 123
Study 26813473 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional treatment plus trimetazidine hydrochloride for 6 months
Number of subjects: 72
Study 26813473 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 72
Study 26813473 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 72
Study 24171895 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture with NSAIDs (zaltoprofen, 80 mg daily)
Number of subjects: 45
Study 24171895 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture alone
Number of subjects: 45
Study 24171895 — intervention group
Group type: COMPARATOR
Intervention: NSAIDs alone
Number of subjects: 45
Study 22378036 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNF-α therapy
Number of subjects: 55
Study 22378036 — intervention group
Group type: COMPARATOR
Intervention: Control group (nontreatment)
Number of subjects: 55
Study 19188654 — intervention group
Group type: EXPERIMENTAL
Intervention: Rx Medibottle
Number of subjects: 0
Study 19188654 — intervention group
Group type: COMPARATOR
Intervention: Oral Syringe
Number of subjects: 0
Study 17473087 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention centers (benchmarking and quality improvement practices)
Number of subjects: 4093
Study 17473087 — intervention group
Group type: COMPARATOR
Intervention: Control centers (standard practices)
Number of subjects: 4093
Study 17473087 — intervention group
Group type: EXPERIMENTAL
Intervention: Best-performing centers (not part of the trial)
Number of subjects: 4093
Study 16879626 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-mm tip catheter
Number of subjects: 82
Study 16879626 — intervention group
Group type: COMPARATOR
Intervention: Cooled tip catheter
Number of subjects: 82
Study 12492742 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of lanzoprazole 30 mg, clarithromycin OD 500 mg, and furazolidone 400 mg, once daily for 7 days (Group A)
Number of subjects: 79
Study 12492742 — intervention group
Group type: COMPARATOR
Intervention: Combination of lanzoprazole 30 mg, clarithromycin OD 500 mg, and furazolidone 200 mg, once daily for 7 days (Group B)
Number of subjects: 79
Study 12492742 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 79
Study 10831005 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl 20 mg
Number of subjects: 418
Study 10831005 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl 60 mg
Number of subjects: 418
Study 10831005 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl 120 mg
Number of subjects: 418
Study 10831005 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl 240 mg
Number of subjects: 418
Study 10831005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 418
Study 8842582 — intervention group
Group type: EXPERIMENTAL
Intervention: 23-day regimen of 20 micrograms ethinylestradiol plus 75 micrograms gestodene
Number of subjects: 60
Study 8842582 — intervention group
Group type: COMPARATOR
Intervention: 21-day regimen of 20 micrograms ethinylestradiol plus 75 micrograms gestodene
Number of subjects: 60
Study 1737667 — intervention group
Group type: EXPERIMENTAL
Intervention: Propionyl-L-carnitine
Number of subjects: 12
Study 1737667 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6483118 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (5.0 micrograms/kg)
Number of subjects: 0
Study 6483118 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (3.0 micrograms/kg)
Number of subjects: 0
Study 6483118 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (Control)
Number of subjects: 0
Study 28436287 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive affect (joy, hope)
Number of subjects: 220
Study 28436287 — intervention group
Group type: EXPERIMENTAL
Intervention: Joy induction
Number of subjects: 220
Study 28535726 — intervention group
Group type: EXPERIMENTAL
Intervention: Arousal reappraisal intervention
Number of subjects: 0
Study 28535726 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 27025124 — intervention group
Group type: EXPERIMENTAL
Intervention: RIPC applied during sevoflurane anesthesia
Number of subjects: 48
Study 27025124 — intervention group
Group type: EXPERIMENTAL
Intervention: RIPC applied during propofol anesthesia
Number of subjects: 48
Study 27025124 — intervention group
Group type: COMPARATOR
Intervention: CONTROL sev (sevoflurane anesthesia without RIPC)
Number of subjects: 48
Study 27025124 — intervention group
Group type: COMPARATOR
Intervention: CONTROL prop (propofol anesthesia without RIPC)
Number of subjects: 48
Study 23428652 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary weekly family‐based behavioral group delivered via telemedicine
Number of subjects: 58
Study 23428652 — intervention group
Group type: COMPARATOR
Intervention: Standard physician visit intervention
Number of subjects: 58
Study 20351375 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 32
Study 20351375 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 32
Study 18420096 — intervention group
Group type: EXPERIMENTAL
Intervention: CoStar drug-eluting stent (DES)
Number of subjects: 1675
Study 18420096 — intervention group
Group type: COMPARATOR
Intervention: Taxus drug-eluting stent (DES)
Number of subjects: 1675
Study 16273750 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricular apex pacing
Number of subjects: 0
Study 16273750 — intervention group
Group type: COMPARATOR
Intervention: Alternative pacing sites and specific algorithms
Number of subjects: 0
Study 13129448 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-cryptoxanthin esters from papaya (1.3 mg)
Number of subjects: 12
Study 13129448 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-esterified beta-cryptoxanthin (1.3 mg)
Number of subjects: 12
Study 13129448 — intervention group
Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 12
Study 10815894 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical removal of tumor
Number of subjects: 93
Study 10815894 — intervention group
Group type: COMPARATOR
Intervention: Antivascular endothelial growth factor antibodies
Number of subjects: 93
Study 10815894 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 93
Study 9028752 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal indomethacin 100 mg
Number of subjects: 78
Study 9028752 — intervention group
Group type: COMPARATOR
Intervention: Intravenous pethidine alone
Number of subjects: 78
Study 1667648 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fibre supplementation (wheat fibre and ispaghula) at an average intake of 16 g per day for six months
Number of subjects: 10
Study 1667648 — intervention group
Group type: COMPARATOR
Intervention: Placebo (during the wash-out period)
Number of subjects: 10
Study 6219156 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled ipratropium plus oral oxtriphylline
Number of subjects: 22
Study 6219156 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fenoterol plus oral oxtriphylline
Number of subjects: 22
Study 6219156 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled ipratropium and fenoterol plus oral oxtriphylline
Number of subjects: 22
Study 6219156 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 31953533 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 15
Study 31953533 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole
Number of subjects: 15
Study 30781529 — intervention group
Group type: EXPERIMENTAL
Intervention: BRINDA internal regression adjustment for CRP and AGP
Number of subjects: 872
Study 30781529 — intervention group
Group type: EXPERIMENTAL
Intervention: Other adjustment methods (arithmetic correction factors, exclusion of subjects with inflammation, higher ferritin cut-off)
Number of subjects: 872
Study 30781529 — intervention group
Group type: EXPERIMENTAL
Intervention: No adjustment for inflammation
Number of subjects: 872
Study 28955064 — intervention group
Group type: EXPERIMENTAL
Intervention: Diathermy incision
Number of subjects: 58
Study 28955064 — intervention group
Group type: COMPARATOR
Intervention: Scalpel incision
Number of subjects: 58
Study 26637166 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (2 mg) administered as 3 monthly loading doses, followed by injections every 2 months over 12 months
Number of subjects: 49
Study 24388619 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone-based stepped-care therapy
Number of subjects: 2375
Study 24388619 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2375
Study 23017669 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy (three cycles of OxMdG: oxaliplatin 85 mg/m², l‐folinic acid 175 mg, fluorouracil 400 mg/m² bolus, then 2400 mg/m² by 46 h infusion) followed by surgery and a further nine cycles of OxMdG
Number of subjects: 150
Study 23017669 — intervention group
Group type: COMPARATOR
Intervention: Postoperative chemotherapy (12 cycles of OxMdG)
Number of subjects: 150
Study 19203899 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX plus bevacizumab
Number of subjects: 0
Study 19203899 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX plus cediranib (AZD2171)
Number of subjects: 0
Study 17381504 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet enriched with MUFA (M)
Number of subjects: 58
Study 17381504 — intervention group
Group type: COMPARATOR
Intervention: Conventional diet (C)
Number of subjects: 58
Study 15288712 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal insulin (human regular insulin 4 x 40 IU/d)
Number of subjects: 38
Study 10931114 — intervention group
Group type: EXPERIMENTAL
Intervention: rBet v 1 fragments (F1: aa1‐74 and F2: aa75‐160)
Number of subjects: 36
Study 10931114 — intervention group
Group type: EXPERIMENTAL
Intervention: rBet v 1 dimer
Number of subjects: 36
Study 10931114 — intervention group
Group type: EXPERIMENTAL
Intervention: rBet v 1 trimer
Number of subjects: 36
Study 10931114 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraderal testing with rBet v 1 trimer
Number of subjects: 36
Study 10931114 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraderal testing with rBet v 1 fragments
Number of subjects: 36
Study 9310280 — intervention group
Group type: EXPERIMENTAL
Intervention: Almokalant at 100 nmol/l
Number of subjects: 82
Study 9310280 — intervention group
Group type: EXPERIMENTAL
Intervention: Almokalant at 50 nmol/l
Number of subjects: 82
Study 9310280 — intervention group
Group type: EXPERIMENTAL
Intervention: Almokalant at 20 nmol/l
Number of subjects: 82
Study 9310280 — intervention group
Group type: EXPERIMENTAL
Intervention: Almokalant at 150 nmol/l
Number of subjects: 82
Study 9310280 — intervention group
Group type: EXPERIMENTAL
Intervention: Almokalant
Number of subjects: 82
Study 8383057 — intervention group
Group type: EXPERIMENTAL
Intervention: ANP 0.5 micrograms kg‐1 bwt
Number of subjects: 50
Study 8383057 — intervention group
Group type: EXPERIMENTAL
Intervention: ANP 1.0 micrograms kg‐1 bwt
Number of subjects: 50
Study 8383057 — intervention group
Group type: EXPERIMENTAL
Intervention: ANP 1.5 micrograms kg‐1 bwt
Number of subjects: 50
Study 8383057 — intervention group
Group type: EXPERIMENTAL
Intervention: ANP 2.0 micrograms kg‐1 bwt
Number of subjects: 50
Study 8383057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 3510479 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloramphenicol instilled after washing with normal saline (2 gm)
Number of subjects: 101
Study 3510479 — intervention group
Group type: COMPARATOR
Intervention: Normal saline washing without chloramphenicol
Number of subjects: 101
Study 30803856 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-power laser phototherapy (3 J/cm2, 808 nm, 100 mW)
Number of subjects: 30
Study 30803856 — intervention group
Group type: COMPARATOR
Intervention: Placebo LPL phototherapy
Number of subjects: 30
Study 28937221 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (800 mg tablet) under fasting conditions
Number of subjects: 23
Study 28937221 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (800 mg tablet) under fed conditions
Number of subjects: 23
Study 28937221 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (800 mg tablet)
Number of subjects: 23